A Phase 1, Prospective, Multi-center, Open-label Study to Assess the Plasma Pharmacokinetics and Lung Penetration of Intravenous (IV) Ceftolozane/Tazobactam in Critically Ill Patients

Trial Profile

A Phase 1, Prospective, Multi-center, Open-label Study to Assess the Plasma Pharmacokinetics and Lung Penetration of Intravenous (IV) Ceftolozane/Tazobactam in Critically Ill Patients

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Aug 2017

At a glance

  • Drugs Ceftolozane/tazobactam (Primary)
  • Indications Nosocomial pneumonia
  • Focus Pharmacokinetics
  • Sponsors Cubist Pharmaceuticals
  • Most Recent Events

    • 13 Jul 2017 Status changed from recruiting to completed.
    • 25 Apr 2017 Preliminary PK, PK/PD and safety results (n=12), presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases
    • 15 Nov 2016 Planned End Date changed from 1 Dec 2016 to 1 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top